Venetoclax Press Release
|10/01/2019 - 17:14||
A team effort uncovers how cancer outwits a targeted drug
Top, from left: Vivian Liu, Steve Carr, Vamsi Mootha. Bottom, from left: Romain Guièze, Cathy Wu, John Doench.
|09/19/2019 - 23:07||
Discerning drivers and passengers in cancer, locating loci for DKD, overcoming exhaustion in T cells, and more.
Welcome to the September 20, 2019 installment of Research Roundup, a recurring snapshot of recent studies published by scientists at the Broad Institute and their collaborators.
|08/14/2019 - 15:20||
New treatment option for certain leukaemia patients in Scotland
A targeted combination treatment for patients with a specific type of blood cancer will soon be available on the NHS in Scotland.
|Cancer Research UK|
|05/16/2019 - 09:10||
Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia
Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced risk of disease progression or death by 67% compared to a current standard-of-care Approval for expanded use of Venclexta offers more adults with chronic lymphocytic leukaemia a new treatment option.
|12/18/2018 - 06:14||
Recent Blog Posts from ASH 2018
The International Myeloma Foundation kicked off the 2018 March Myeloma Action month with the focus on the #MyelomaWarrior. On the plane I was on from DFW to SAN to attend the 60th American Society of Hematology Annual Meeting & Exposition held in San Diego from December 1 – 4, 2018, there was a Warrior, in […]
|12/04/2018 - 17:48||
Late-Breaking Clinical Trials Advance Targeted Therapies for Patients with CLL and Multiple Myeloma
Three studies being presented today during the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego offer more targeted solutions for managing CLL and multiple myeloma.
|11/01/2018 - 03:52||
Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities
The phase III CLL14 study compared Venclexta/Venclyxto in combination with Gazyva/Gazyvaro to standard-of-care Gazyva/Gazyvaro plus chlorambucil Data will be submitted to health authorities and presented at an upcoming medical meeting.
|11/01/2018 - 03:02||
Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Approval is based on randomised phase III MURANO study showing that fixed duration of treatment with Venclyxto plus MabThera is well tolerated and reduced risk of disease progression or death by 83% compared to a current standard of care New combination provides a chemotherapy-free option for treating people with chronic lymphocytic leukaemia whose disease has returned after previous treatment.
|08/17/2018 - 09:43||
Tolero Pharmaceuticals announces clinical research collaboration with AbbVie for acute myeloid leukemia trial.
SALT LAKE CITY, August 17, 2018 -- Tolero Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for hematologic and oncologic diseases, has entered into a clinical research collaboration with AbbVie, a research-based global biopharmaceutical company, exploring the potential of combination therapy with AbbVie’s venetoclax and Tolero’s investigational agent, alvocidib, for the treatment of relapsed/refractory acute myeloid leukemia (AML).
|06/10/2018 - 23:41||
Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia
Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that the United States Food and Drug Administration (FDA) has approved Venclexta® (venetoclax) in combination with Rituxan® (rituximab) for the treatment of people with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. Venclexta is being developed by AbbVie and Roche. It is jointly commercialised by AbbVie and Genentech, a member of the Roche Group, in the United States and commercialised by AbbVie outside of the United States.
|08/12/2016 - 06:17||
Venetoclax Safe, Shows Promise in Patients With Acute Myelogenous Leukemia
PHILADELPHIA — Patients whose acute myelogenous leukemia (AML) had relapsed or was resistant to chemotherapy and those who were deemed unable to tolerate chemotherapy experienced responses to the selective BCL-2 inhibitor venetoclax (Venclexta), with complete remissions in some, according to phase II clinical trial data published in Cancer Discovery, a journal of the American Association for Cancer Research.
|04/12/2016 - 08:51||
Roche announces FDA grants Venclexta(venetoclax) accelerated approval for people with hard-to-treat type of chronic lymphocytic leukemia
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Venclexta™ (venetoclax) for the treatment of people with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy. The pivotal study showed a clinically meaningful improvement (overall response rate, ORR) in 80.2 percent of people (95 percent CI 71.3-87.3). Venclexta is the first approved medicine designed to help restore a process in which cells self-destruct (apoptosis) by selectively blocking the BCL-2 protein and is Roche’s tenth new medicine approved in the past seven years.
|04/11/2016 - 19:43||
Genentech Announces FDA Grants Venclexta (Venetoclax) Accelerated Approval for People with a Hard-To-Treat Type of Chronic Lymphocytic Leukemia
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) granted accelerated approval to VenclextaTM (venetoclax) for the treatment of people with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy. The pivotal study showed a clinically meaningful improvement (overall response rate, ORR) in 80.2 percent of people (95 percent CI 71.3-87.3). Venclexta is the first approved medicine designed to help restore a process in which cells self-destruct (apoptosis) by selectively blocking the BCL-2 protein and is Genentech’s tenth new medicine approved in the past seven years.